49 results
8-K
SYRS
Syros Pharmaceuticals Inc.
12 Dec 22
Regulation FD Disclosure
7:48am
, the Company issued a press release announcing new data presented at the 64th Annual Meeting of the American Society of Hematology from the safety lead
8-K
SYRS
Syros Pharmaceuticals Inc.
20 Sep 21
Regulation FD Disclosure
4:02pm
things, new data presented at the European Society for Medical Oncology Congress (“ESMO 2021”) from the dose-escalation portion of the Company’s
8-K
EX-99.2
SYRS
Syros Pharmaceuticals Inc.
25 May 23
Regulation FD Disclosure
5:10pm
in two posters at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, in Chicago, Illinois.
“We
8-K
EX-99.2
SYRS
Syros Pharmaceuticals Inc.
12 Dec 22
Regulation FD Disclosure
7:48am
session at the 64th American Society of Hematology (ASH) Annual Meeting, taking place in New Orleans, LA.
“As a physician devoted to the care
8-K
EX-99.2
SYRS
Syros Pharmaceuticals Inc.
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
populations. The data is being presented today in oral presentations at the 62nd American Society of Hematology (ASH) Annual Meeting. In a separate
8-K
EX-99.1
xmp5jdiulu x5fve
3 Dec 18
Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting
8:07am
8-K
EX-99.3
k85cb m5l103
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-99.1
crc30l
15 Nov 18
Regulation FD Disclosure
4:03pm
8-K
m21xzicgu8xfx6
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-99.1
pyem9lb46iv8
25 May 23
Regulation FD Disclosure
5:10pm